enGene (NASDAQ:ENGN) Earns “Outperform” Rating from Oppenheimer

enGene (NASDAQ:ENGN)‘s stock had its “outperform” rating restated by analysts at Oppenheimer in a report released on Tuesday, Benzinga reports. They currently have a $30.00 target price on the stock. Oppenheimer’s price target suggests a potential upside of 368.02% from the company’s previous close.

Separately, Morgan Stanley reissued an “overweight” rating and set a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.67.

enGene Trading Down 11.1 %

Shares of NASDAQ:ENGN opened at $6.41 on Tuesday. The company has a market capitalization of $283.10 million, a PE ratio of -3.86 and a beta of -0.68. enGene has a 12-month low of $4.94 and a 12-month high of $43.00. The business has a 50 day moving average of $7.24 and a two-hundred day moving average of $11.03. The company has a current ratio of 19.52, a quick ratio of 42.80 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, analysts forecast that enGene will post -1.49 EPS for the current year.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENGN. Altitude Crest Partners Inc. purchased a new stake in shares of enGene during the first quarter worth about $2,039,000. SR One Capital Management LP acquired a new stake in enGene in the 2nd quarter worth about $4,715,000. Omega Fund Management LLC purchased a new stake in enGene during the 4th quarter worth approximately $10,441,000. Logos Global Management LP increased its stake in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of enGene during the first quarter valued at approximately $17,095,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.